RESUMEN
BACKGROUND: Cannabis is the most widespread illicit drug among young adults globally. This study aimed to detect the extent of cannabis use in the study population and its impact on users' lives. We hypothesized that early cannabis use would significantly predict later high-risk use. METHODS: An online cross-sectional study using a self-administered questionnaire was conducted in December 2021, aiming to explore the extent of cannabis use among students and detect changes in behavior and impact on their lives. The results were analyzed statistically and correlated. RESULTS: Out of the 297 enrolled participants with a mean age of 21.0 ± 2.1 years, 101 (33.9 %) had used cannabis at least once (50 males). The mean age at first cannabis use was 18.5 ± 2.11 years. Over 90 % reported easy access to it. Behavioral changes following use were reported by 41.6 %, but none except one sought help. Age at first cannabis use was negatively correlated with past-month and past-year use. Cannabis use before midday was positively correlated with age on the first try. DISCUSSION: The prevalence of cannabis use was higher than the European average. Confirming the study's hypothesis, the younger the age at first use, the heavier the past-year and past-month use, which also agrees with previous studies. Cannabis consumption before noon was linked to increased use, and alarmingly, there was reluctance to seek help despite a high proportion of behavioral changes after use. CONCLUSION: As the legislation on the use of cannabis changes rapidly, and given the increasing popularity of cannabis, there is a need for continued research on how various factors differentially impact its use. HIPPOKRATIA 2021, 25 (4):162-168.
RESUMEN
OBJECTIVE: Parathyroidectomy (PTx) has an established benefit in patients with symptomatic primary hyperparathyroidism (PHPT). However, its efficacy in mild asymptomatic PHPT has not been proven. This study aimed to systematically review and meta-analyze the best available evidence from randomized-controlled trials comparing the efficacy of PTx over conservative management (non-PTx) on skeletal outcomes [fractures and bone mineral density (BMD)], nephrolithiasis risk and quality of life (QoL) in patients with mild asymptomatic PHPT. METHODS: A comprehensive literature search was conducted in PubMed, Scopus and Cochrane databases, from conception to February 23, 2020. Data were extracted from the studies that fulfilled the eligibility criteria and were synthesized quantitatively (fixed or random effects model) as relative risks and percentage mean differences (MD) with 95% confidence intervals (CI). I2 index was employed for heterogeneity. RESULTS: Four studies were included in the meta-analysis. There was no difference in fracture risk between PTx and active surveillance. The PTx group demonstrated higher BMD [MD 3.55% (95% CI 1.81, 5.29) in lumbar spine and 3.44% (95% CI 1.39, 5.49) in total hip, without difference in femoral neck and forearm] and lower calcium concentrations (MD - 13.26%, 95% CI - 7.10, - 19.43) compared with the non-PTx group. No difference was observed between groups regarding nephrolithiasis or QoL indices, except for general health (higher in PTx group). CONCLUSIONS: In patients with mild asymptomatic PHPT, PTx increases BMD and reduces serum calcium concentrations. However, its superiority over active surveillance in terms of fracture risk, nephrolithiasis and QoL cannot be supported by current data.
